This was further supported by the observation that hepatocyte‐specific asprosin knockdown alleviated hepatic steatosis, inflammation, and fibrosis in an HFCDAA diet‐induced mouse model, while liver‐specific asprosin overexpression via adeno‐associated virus delivery exacerbated hepatic steatosis, liver injury, and dyslipidemia. Here, FBN1 is linked to fatty liver disease.